On 13 November 2014, the Committee for Orphan Medicinal Products (COMP) issued a positive opinion on the application for orphan drug designation for Oncos Therapeutics’ lead compound ONCOS-102, a genetically modified serotype 5/3 adenovirus coding for granulocyte macrophage colony-stimulating factor. The application covered malignant mesothelioma.
Oncos will, in due course, receive the opinion together with the summary report and subsequently the EMA Public Summary of Opinion for comments and finally the Decision from the European Commission.
COMP is the committee at the European Medicines Agency (EMA) that is responsible for reviewing applications from people or companies seeking orphan-medicinal-product designation.